Novo Holdings A/S is pleased to announce the appointment of Peder Holk Nielsen, former CEO of Novozymes, and Per G.H. Löfberg, former Executive Vice President of CVS Health, as new members of the Novo Advisory Group.

The appointment of the two new members will further strengthen the competencies of the Novo Advisory Group as Novo Holdings continues to increase its life science investments in the future.

Kasim Kutay, CEO of Novo Holdings, says: “We are delighted that Peder Holk Nielsen and Per Löfberg are joining the Novo Advisory Group. Both are highly respected business leaders with impressive track records and bring in-depth knowledge of sectors that are of great importance to Novo Holdings, including the bioindustrial sector and the United States healthcare market.”

Peder Holk Nielsen served as President and CEO of Novozymes, a world leader in biological solutions, until stepping down January 2020. During his nearly 7 years in leadership, the market value of Novozymes approximately doubled.

He has extensive knowledge and understanding of the Novo Group having held various leadership positions in his 35 years with Novo Nordisk A/S and Novozymes A/S.

Peder Holk Nielsen says: “I have been following the work of Novo Holdings for several years, and I am very impressed with its track record. I am delighted to be part of such an ambitious group, and I look forward to using my experience to help Novo Holdings further increase its investments to the benefit of the Novo Nordisk Foundation.”

Per G.H. Löfberg is former Executive Vice President of CVS Health, a leading United States healthcare company that owns several brands, including CVS Pharmacy, a retail pharmacy chain, and Aetna, a health insurance provider.

He has spent his entire career with companies in the United States and has extensive knowledge and understanding of its healthcare market, especially in terms of payer dynamics and services for the life science industry. Before joining CVS Health, Löfberg served as President and CEO of Generation Health, an early-stage company focused on benefit management in genetic testing. He was also co-founder and CEO of Merck Capital Ventures, a captive venture capital investment company funded by Merck & Co., Inc. investing in emerging healthcare technologies.

Per Löfberg says: “I am very pleased to be joining the Novo Advisory Group. Novo Holdings is a recognized leading life science investor with a great purpose, and I particularly look forward to using my knowledge from the American healthcare sector to assist Novo Holdings with adding to their investments in this market as well as other sectors.”

About Peder Holk Nielsen

Danish citizen

**Career
**2013–2020       President and CEO, Novozymes
2007–2013       Executive Vice President, Novozymes: head of the enzyme business
2000–2007      Executive Vice President, Novozymes: head of sales, marketing and supply chain
1995–2000       Corporate Vice President, Novo Nordisk: head of sales and marketing in the enzymes business (1998–2000) and head of development in the enzyme business (1995–1998)
1990–1995       Vice President, Novo Nordisk, head of enzyme technology, a research unit in enzymes R&D
1984–1990       Manager and Director, Novo A/S and Novo Nordisk: product manager, marketing manager and head of business development in the enzymes business

He served as a trustee of the United States Council for International Business, the Eisenhower Foundation and a member of the International Chamber of Commerce G20 CEO Advisory Group until he stepped down as the CEO of Novozymes. He has served on the boards of Hempel A/S and LEO Pharma A/S.

**Education
**1985                      PhD, Chemical Engineering, Technical University of Denmark
1985                      Bachelor of International Business Management, Copenhagen Business School
1984                      MSc, Chemical Engineering, Technical University of Denmark

About Per G.H. Löfberg

Born in Sweden and United States citizen

**Career
**2010–2016          Executive Vice President, CVS Health
2008–2010         President & CEO, Generation Health, Inc.
2001–2008         President, Merck Capital Ventures, LLC
1987–2000         Medco Health Solutions, Inc. (President, 1994–2000)
1973–1987           Vice President and Partner, Boston Consulting Group, Inc.

**Education
**1973:                      MSc, Carnegie Mellon University, United States
1971                        BSc, Stockholm School of Economics, Sweden

He is a trustee of Our Sisters’ School, New Bedford, United States.